Phase 3
Completed N=346
Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea
Source: ClinicalTrials.gov NCT00250458 ↗Enrolled (actual)
346
Serious AEs
0.0%
Results posted
Jun 2010
Primary outcomePrimary: Participants With Elimination of Nausea at 2 Hours Postdose — 130; 57; 55; 35 Participants
Summary
Study to test the effectiveness of a marketed drug in the treatment of migraine-associated nausea.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Participants With Elimination of Nausea at 2 Hours Postdose |
130; 57; 55; 35 | — |
| SECONDARY Participants With Pain Relief at 2 Hours Postdose |
129; 50; 56; 42 | — |
Eligibility Criteria
Inclusion Criteria
- 6-month history of migraine, moderate to severe migraine attacks with nausea, 1-6 migraine attacks per month
Exclusion Criteria
- Heart disease, high blood pressure
Data sourced from ClinicalTrials.gov (NCT00250458). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.